Therapeutic Solutions International Announces Reduction of COVID-19 Associated Cognitive Decline by QuadraMune® Nutraceutical in Animal Model
New Data Suggests Possible Efficacy of QuadraMune® in Treatment of COVID-19 “Brain Fog”
In a series of experiments, mice were treated with artificially generated spike protein on a daily basis for 7 days in order to mimic infection with SARS-CoV-2, the virus responsible for COVID-19 disease. One group of mice received saline and two groups received a low and high dose of QuadraMune, a fourth group of mice received no treatment. Significant dose dependent preservation of cognitive activity was observed in mice receiving QuadraMune. Additionally, reduction of microglial activation, a sign of neural inflammation was reported.
QuadraMune is an immune modulating nutraceutical whose use in treatment of COVID-19 is covered by issued US Patent #11,229,674.
“The more we learn about COVID-19 brain after-effects, the more we see a consistent pattern of inflammatory cytokines and inflammatory cells eliciting changes that cause chronic brain degeneration,” said Dr.
COVID-19 associated brain changes have been shown to cause severe damage in certain individuals. In one recent peer reviewed study, COVID-19 brain pathology was shown to be similar to Alzheimer’s Disease1.
“We are only now beginning to see the long-term consequences of COVID-19 infection. We believe that the potent anti-inflammatory and neuroregenerative effects of QuadraMune may be particularly useful in leveraging the body’s own mechanisms to mediate post-infection healing,” said
About
1 Alzheimer's‐like signaling in brains of COVID‐19 patients - Reiken - - Alzheimer's & Dementia -
View source version on businesswire.com: https://www.businesswire.com/news/home/20220207005474/en/
ir@tsoimail.com
Source: